MSU-42011

• Description:

  MSU-42011 is an orally active retinoid X receptor (RXR) agonist. MSU-42011 inhibits the iNOS activity and reduces the expression of p-ERK protein. MSU-42011 has immunomodulatory and antitumor activity[1].

• UNSPSC:

  12352005

• Target:

  NO Synthase; RAR/RXR

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/msu-42011.html

• Concentration:

  10mM

• Purity:

  98.43

• Solubility:

  DMSO : 125 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C (C1=CN=C (N (CC (C) C) C2=CC (C (C) (C) C) =CC (C (C) (C) C) =C2) C=C1) O

• Molecular Formula:

  C24H34N2O2

• Molecular Weight:

  382.54

• References & Citations:

  [1]Moerland JA, et al. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Sci Rep. 2020 Dec 17;10 (1) :22244.|[2]Ana S Leal, et al. The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers (Basel) . 2021 Oct 6;13 (19) :5004.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2456434-36-7